Cerenis Therapeutics has acquired Lypro Biosciences assets, a portfolio of proprietary drug delivery nanotechnology for an undisclosed amount.
For the company, the acquisition is the latest step in development the next generation of multiple targeted drug delivery nanotechnologies associated with HDL therapy.
Lypro will receive single digit regulatory milestones as well as single digit royalties depending on products sales each year.
Using its existing technologies with Lypro’s NanoDisk discoidal HDL, Cerenis said it is positioned to utilise HDL related particles to selectively target a wide variety of tissues
“We look forward to initiating the Phase I trial of NanoDisk and advancing other HDL-based assets,” said Cerenis CEO Jean-Louis Dasseux.